Profile data is unavailable for this security.
About the company
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
- Revenue in USD (TTM)1.40bn
- Net income in USD16.90m
- Incorporated2013
- Employees1.31k
- LocationSarepta Therapeutics Inc215 1st St Ste 415CAMBRIDGE 02142-1213United StatesUSA
- Phone+1 (617) 274-4000
- Fax+1 (302) 636-5454
- Websitehttps://www.sarepta.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
KBR Inc | 7.07bn | -258.00m | 8.39bn | 34.00k | -- | 5.98 | -- | 1.19 | -1.91 | -1.91 | 52.67 | 10.46 | 1.25 | -- | 5.56 | 207,970.60 | -4.45 | 0.4725 | -6.46 | 0.6678 | 13.86 | 12.18 | -3.58 | 0.4122 | -- | 1.17 | 0.5678 | 340.00 | 5.97 | 7.20 | -240.21 | -- | 36.31 | 11.03 |
Elanco Animal Health Inc | 4.37bn | -1.30bn | 8.99bn | 9.30k | -- | 1.48 | -- | 2.06 | -2.64 | -2.64 | 8.84 | 12.26 | 0.2931 | 1.21 | 4.28 | 469,354.80 | -8.74 | -3.27 | -9.65 | -3.65 | 55.28 | 54.28 | -29.83 | -11.53 | 1.96 | 0.853 | 0.4877 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
Insmed Inc | 315.49m | -746.89m | 9.30bn | 912.00 | -- | -- | -- | 29.46 | -5.23 | -5.23 | 2.20 | -3.13 | 0.2357 | 0.8971 | 9.32 | 345,936.40 | -55.80 | -40.96 | -72.23 | -46.88 | 78.07 | 77.99 | -236.74 | -212.92 | 1.61 | -16.08 | 1.64 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
Catalent Inc | 4.14bn | -1.18bn | 9.95bn | 17.80k | -- | 2.74 | -- | 2.41 | -6.48 | -6.48 | 22.69 | 20.06 | 0.3993 | 4.36 | 2.87 | 232,303.40 | -11.36 | 2.88 | -12.91 | 3.26 | 18.96 | 31.03 | -28.44 | 6.35 | 1.74 | -0.4346 | 0.5797 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
Charles River Lbrtrs ntrntl Inc | 4.11bn | 438.82m | 10.83bn | 20.00k | 24.67 | 2.97 | 14.00 | 2.63 | 8.52 | 8.52 | 79.74 | 70.67 | 0.5187 | 8.38 | 5.22 | 205,579.80 | 5.69 | 6.46 | 6.53 | 7.62 | 36.45 | 36.99 | 10.97 | 11.58 | 1.37 | 4.80 | 0.4183 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
Sarepta Therapeutics Inc | 1.40bn | 16.90m | 11.32bn | 1.31k | 1,502.70 | 11.77 | 192.68 | 8.06 | 0.0797 | 0.0797 | 14.75 | 10.17 | 0.4466 | 0.5758 | 4.66 | 1,067,960.00 | 0.5378 | -21.63 | 0.6577 | -25.75 | 88.18 | 86.65 | 1.20 | -77.05 | 3.44 | -- | 0.5632 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
United Therapeutics Corporation | 2.50bn | 1.05bn | 12.12bn | 1.17k | 12.93 | 2.26 | 10.96 | 4.85 | 21.13 | 21.13 | 50.24 | 120.76 | 0.3891 | 2.50 | 11.31 | 2,138,956.00 | 16.36 | 10.38 | 18.03 | 11.27 | 88.87 | 91.47 | 42.05 | 29.25 | 3.64 | -- | 0.101 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
BIO-TECHNE Corp | 1.15bn | 202.97m | 12.12bn | 3.05k | 61.15 | 6.01 | 38.65 | 10.50 | 1.26 | 1.26 | 7.16 | 12.79 | 0.4339 | 2.20 | 5.20 | 378,452.80 | 7.63 | 9.57 | 8.07 | 10.20 | 66.80 | 67.35 | 17.59 | 21.91 | 2.88 | 14.00 | 0.1619 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
Medpace Holdings Inc | 1.96bn | 312.32m | 12.20bn | 5.80k | 40.11 | 18.12 | 35.89 | 6.21 | 9.81 | 9.81 | 61.73 | 21.72 | 1.23 | -- | 7.31 | 332,680.00 | 19.58 | 13.94 | 46.20 | 23.18 | 27.99 | 28.84 | 15.92 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
Viatris Inc | 15.36bn | -56.10m | 12.54bn | 38.00k | -- | 0.6263 | 4.74 | 0.8162 | -0.0499 | -0.0499 | 12.75 | 16.81 | 0.3179 | 2.33 | 5.29 | 404,242.10 | -0.1161 | 0.0887 | -0.1356 | 0.1061 | 43.26 | 40.29 | -0.3652 | 0.2891 | 1.17 | 2.63 | 0.473 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
Natera Inc | 1.21bn | -365.46m | 13.01bn | 3.28k | -- | 16.31 | -- | 10.76 | -3.13 | -3.13 | 10.31 | 6.50 | 0.8673 | 14.36 | 4.51 | 368,237.70 | -26.23 | -36.17 | -33.37 | -46.60 | 50.28 | 45.88 | -30.24 | -56.15 | 3.98 | -- | 0.3141 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
Incyte Corp | 3.77bn | 745.44m | 13.15bn | 2.52k | 17.78 | 2.44 | 15.83 | 3.49 | 3.29 | 3.29 | 16.64 | 24.02 | 0.5827 | 4.52 | 5.50 | 1,492,815.00 | 11.53 | 9.07 | 14.16 | 11.02 | 93.73 | 94.97 | 19.78 | 13.68 | 3.43 | -- | 0.006 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
Neurocrine Biosciences, Inc. | 1.98bn | 369.70m | 13.43bn | 1.45k | 36.68 | 5.63 | 34.25 | 6.78 | 3.64 | 3.64 | 19.47 | 23.72 | 0.6797 | 1.10 | 4.71 | 1,415,714.00 | 12.68 | 9.77 | 15.58 | 12.19 | 98.05 | 98.51 | 18.65 | 14.79 | 2.47 | -- | 0.049 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 8.66m | 9.23% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 4.85m | 5.17% |
Capital Research & Management Co. (International Investors)as of 31 Mar 2024 | 4.82m | 5.13% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 4.55m | 4.85% |
Avoro Capital Advisor LLCas of 31 Mar 2024 | 4.34m | 4.63% |
Wellington Management Co. LLPas of 31 Mar 2024 | 3.25m | 3.46% |
Farallon Capital Management LLCas of 31 Mar 2024 | 2.45m | 2.61% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.12m | 2.26% |
T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 1.93m | 2.06% |
EcoR1 Capital, LLCas of 31 Mar 2024 | 1.92m | 2.05% |